Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Multiple Myeloma 4Leukemia, Lymphocytic, Chronic, B-Cell 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Lymphoma, Non-Hodgkin 2Pancreatic Neoplasms 1Leukemia, Prolymphocytic 1Leukemia, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1

Interventions

ofatumumab 10Rituximab 6ibrutinib 5Cyclophosphamide 5fludarabine phosphate 4Bendamustine Hydrochloride 4fludarabine 3Lenalidomide 3Alemtuzumab 3spebrutinib 2navitoclax 2acalabrutinib 2KW-2478 2venetoclax 1tirabrutinib 1obinutuzumab 1idelalisib 1dinaciclib 1Tablets 1Stem Cell Transplantation 1Rabeprazole 1Pentostatin 1Metronidazole 1Methylprednisolone 1Magnetic Resonance Imaging 1MLN 8237 1Leukapheresis 1Lansoprazole 1Itraconazole 1Immunotherapy, Adoptive 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, B-Cell × dinaciclib × Clear all
NCT00871663 2015-04-20

Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)

Merck Sharp & Dohme LLC

Phase 1 Completed
123 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡